Altria Group, Inc. is a U.S. tobacco company that manufactures and sells smokeable, oral, and e-vapor nicotine products. Its primary operating subsidiaries include Philip Morris USA, which produces Marlboro cigarettes; John Middleton, which manufactures Black & Mild cigars; U.S. Smokeless Tobacco Company, which sells Copenhagen and Skoal moist smokeless tobacco; Helix Innovations, which produces on! oral nicotine pouches; and NJOY, which markets NJOY ACE and NJOY DAILY e-vapor products. The company also holds a majority interest in Horizon Innovations, a joint venture with Japan Tobacco for the U.S. commercialization of heated tobacco stick products. Altria operates primarily within the United States, selling to wholesalers and large retail organizations. It maintains equity investments in Anheuser-Busch InBev and Cronos Group. The company’s business segments are smokeable products, oral tobacco products, and e-vapor products.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Tobacco Homepage altria.com
Sector Consumer Defensive IR page investor.altria.com/press-releases/default.aspx
Tags
cigarettes, cigars, smokeless tobacco, nicotine pouches, e-vapor products, heated tobacco, consumer staples, brand management, distribution, harm reduction, Philip Morris USA, Marlboro, John Middleton, Black & Mild, U.S. Smokeless Tobacco Company, Copenhagen, Skoal, Red Seal, Helix Innovations, on!, NJOY, NJOY ACE, NJOY DAILY, Horizon Innovations, Anheuser-Busch InBev, Cronos Group, Altria Group Distribution Company, Altria Client Services, Ploom
Press page investor.altria.com/press-releases/default.aspx

Metrics

Valuation  
Market cap $ 112.016B
Market cap (USD) $ 112.016B
P/E 13.88
PEG 2.17
P/BV -50.34
P/S 4.76
P/OCF 11.89
P/FCF 12.35
Dividend yield 6.4%
Turnover / mcap —
Returns  
ROE -198.4%
ROI 31.3%
ROIC 33.0%
Profit margin 29.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 6.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 5.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 23.279B 24.018B 24.483B 25.096B 26.013B 26.153B 25.11B 25.364B 25.576B 25.744B 25.434B 24.522B 24.466B 24.618B 23.8B 24.363B 23.556B 19.356B 73.801B 101.407B 97.854B 89.61B 81.832B 80.408B 89.924B 80.356B
Net profit 6.947B 11.264B 8.13B 5.764B 2.475B 4.467B -1.293B 6.963B 10.222B 14.239B 5.241B 5.07B 4.535B 4.183B 3.39B 3.905B 3.206B 4.93B 9.786B 12.022B 10.435B 9.416B 9.204B 11.102B 8.56B 8.51B
Free cash flow 9.074B 8.611B 9.091B 8.051B 8.236B 8.154B 7.591B 8.153B 4.723B 3.602B 5.581B 4.5B 4.244B 3.779B 3.508B 2.599B 3.17B — — 11.132B 8.854B 8.977B 8.842B 8.603B 6.971B 9.362B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 57.66 52.29 40.34 45.71 47.39 41 49.91 49.39 71.41 67.62 58.21 49.27 38.39 31.44 29.65 24.62 19.63 15.05 70.25 81.22 — — — — — —
Price performance 12m 0.1 0.3 -0.12 -0.04 0.16 -0.18 0.01 -0.31 0.06 0.16 0.18 0.28 0.22 0.06 0.2 0.25 0.3 -0.79 -0.14 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 151M 142M 142M 152M 137M 47M 48M 71M 177M 263M
↳ YoY growth +21.8% -6.0% 0% +7.0% -9.9% -65.7% +2.1% +47.9% +149.3% +48.6%
↳ 5y CAGR -10.8% -6.0% +4.3% +4.2% +2.0% -20.8% -19.5% -12.9% +3.1% +13.9%
Borrowings, current (USD) 0.00 864M 13.8B 1B 1.5B 1.11B 1.56B 1.12B 1.53B 1.57B
Borrowings, non-current (USD) 13.9B 13B 11.9B 27B 28B 26.9B 25.1B 25.1B 23.4B 24.1B
Cash and deposits (USD) 4.57B 1.25B 1.33B 2.12B 4.95B 4.54B 4.03B 3.69B 3.13B 4.47B
Intangible assets (USD) 12B 12.4B 12.3B 12.7B 12.6B 12.3B 12.4B 13.7B 13B 11.9B
Net debt (borrowings + leases - cash) (USD) 9.31B 12.6B 24.4B 25.9B 24.5B 23.5B 22.7B 22.5B 21.8B 21.2B
Cash flow detail
Operating cash flow (USD) 3.79B 4.92B 8.39B 7.84B 8.39B 8.41B 8.26B 9.29B 8.75B 9.29B
Purchases of property, plant and equipment (USD) -189M -199M -238M -246M -231M -169M -205M -196M -142M -216M
Change in receivables (cash effect) (USD) -27M 10M 0.00 -8M 20M -18M -21M 6M -106M -86M
Change in inventories (cash effect) (USD) -34M -171M -129M 42M 2M 57M 14M -15M 102M -27M
Change in payables (cash effect) (USD) -6M -55M 27M -79M 53M 163M 92M 38M 116M 34M
Dividends paid (cash effect) (USD) -4.51B -4.81B -5.42B -6.07B -6.29B -6.45B -6.6B -6.78B -6.85B -6.96B
Share buybacks (cash effect) (USD) -1.03B -2.92B -1.67B -845M 0.00 -1.68B -1.83B -1B -3.4B -1B
Interest paid (cash effect) (USD) -775M -696M -704M -1.1B -1.25B -1.19B -1.12B -1.12B -1.11B -1.11B
Income taxes paid (cash effect) (USD) -4.66B -3.04B -2.31B -1.98B -2.62B -2.67B -2.66B -1.89B -1.8B -1.7B
Operating cash flow before change in receivables (USD) 3.82B 4.91B 8.39B 7.85B 8.37B 8.42B 8.28B 9.28B 8.86B 9.38B
Free cash flow (OCF - PPE - intangibles) (USD) 3.6B 4.72B 8.15B 7.59B 8.15B 8.24B 8.05B 9.09B 8.61B 9.07B
Income detail
Research and development expense (USD) 203M 241M 252M 168M 131M 145M 162M 220M 208M 195M
↳ 5y CAGR +9.7% +12.1% +10.5% +0.1% -6.8% -6.5% -7.6% -2.7% +4.4% +8.3%
Total comprehensive income (USD) 15.5B 10.4B 6.73B -1.62B 2.98B 3.76B 6.05B 8.23B 11.5B 6.72B
Comprehensive income to owners (USD) 15.5B 10.4B 6.72B -1.61B 2.99B 3.76B 6.05B 8.23B 11.5B 6.72B
Reported Feb 27, 2017 Feb 27, 2018 Feb 26, 2019 Feb 25, 2020 Feb 26, 2021 Feb 25, 2022 Feb 27, 2023 Feb 27, 2024 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/29/2026

Download this Press Release PDF Format (opens in new window)

RICHMOND, Va.--(BUSINESS WIRE)-- Altria Group, Inc. (NYSE: MO) today reports our 2026 third-quarter and nine-months business results and raises our guidance for 2026 full-year adjusted diluted earnings per share (EPS).

“Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future,” said Sal Mancuso, Altria’s Chief Executive Officer.

“In smokeable products, PM USA grew operating companies income through its data-driven, total portfolio approach, with Cowboy Cut strengthening Marlboro’s premium position and Basic continuing to gain share in discount. In smoke-free, Helix made meaningful progress by expanding on! PLUS 12-milligram nationwide, investing in brand-building initiatives and preparing for its next wave of innovation, which is now underway with the introduction of Blueberry Mint and Mango Pineapple flavor extensions at retail.”

“Our highly cash-generative businesses supported significant returns to shareholders through dividends and share repurchases, while we continued to invest in support of our Vision. In August, we announced our 61st dividend increase in 57 years, and our Board of Directors (Board) recently authorized a $1 billion expansion of our existing share repurchase program.”

“Our strong performance through the first nine months and confidence in our full-year plan allowed us to raise our earnings guidance for the year. We now expect to deliver adjusted diluted EPS in a range of $5.66 to $5.74, representing a growth rate of 4.5% to 6.0% from a base of $5.42 in 2025.”

Altria Headline Financials1

($ in millions, except per share data) Q3 2026 **Change vs. **Q3 2025 Q3 YTD 2026 **Change vs. **Q3 YTD 2025
Net revenues $6,132 1.0% $17,671 1.4%
Revenues net of excise taxes $5,441 3.6% $15,555 3.3%
Reported effective tax rate 23.6% 0.8 pp 22.9% (3.1) pp
Adjusted effective tax rate 23.0% (0.1) pp 23.0% (0.3) pp
Reported diluted EPS $1.51 7.1% $4.18 21.2%
Adjusted diluted EPS $1.52 4.8% $4.33 5.1%

1 “Adjusted” financial measures presented in this release exclude the impact of special items. See “Basis of Presentation” for more information and see the schedules to this press release for reconciliations to corresponding GAAP measures.

As previously announced, a conference call with the investment community and news media will be webcast on October 29, 2026 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts .

Cash Returns to Shareholders

Share Repurchase Program

  • In the third quarter, we repurchased 5.9 million shares at an average price of $68.52 per share, for a total cost of $400 million.
  • Through the first nine months, we repurchased 11.2 million shares at an average price of $65.78 per share, for a total cost of $735 million.
  • Yesterday, our Board authorized a $1 billion expansion of our existing share repurchase program, which now expires on December 31, 2027.

Dividends

  • We paid dividends of $1.7 billion and $5.3 billion in the third quarter and first nine months, respectively.
  • In August, our Board increased our regular quarterly dividend by 4.7%, marking the 61 st increase in the past 57 years. Our current annualized dividend rate is $4.44 per share.
  • We maintain our progressive dividend goal that targets mid-single digits dividend per share growth annually through 2028.

Smoke-Free Portfolio Update

  • Helix recently expanded its on! PLUS portfolio with two new flavors, Blueberry Mint and Mango Pineapple, across 6-, 9- and 12-milligram nicotine strengths.
  • In the fourth quarter, Helix plans to further expand its on! PLUS portfolio with Watermelon Mint, across 6-, 9- and 12-milligram nicotine strengths, in select retail locations.

2026 Full-Year Guidance

We expect our 2026 full-year adjusted diluted EPS to be in a range of $5.66 to $5.74, representing a growth rate of 4.5% to 6.0% from a base of $5.42 in 2025.

As previously disclosed, our guidance contemplates:

(i) the impact of moderated e-vapor industry growth on combustible and e-vapor product volumes;

(ii) increased macroeconomic uncertainty facing adult nicotine consumers;

(iii) investments in support of our contract manufacturing capabilities;

(iv) that NJOY ACE does not return to the marketplace in 2026;

(v) reinvestment of anticipated cost savings related to our Optimize & Accelerate initiative (Initiative); and

(vi) investments in support of our Vision.

Our full-year adjusted diluted EPS guidance range excludes the impact of certain income and expense items that our management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, charges related to restructuring and other exit activities, asset impairment charges, acquisition, disposition and integration-related items, equity investment-related special items, certain income tax items, charges associated with tobacco and health and certain other litigation items, resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the Master Settlement Agreement (NPM Adjustment Items) and amortization expense associated with definite-lived intangible assets (amortization of intangibles). See Table 1 below for the income and expense items for the third quarter and first nine months of 2026.

Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding GAAP measure for, or reconciliation to, our adjusted diluted EPS guidance.

ALTRIA GROUP, INC.

See “Basis of Presentation” for an explanation of the financial measures and reportable segments discussed in this release.

Financial Performance

Third Quarter

  • Net revenues increased 1.0% to $6.1 billion, primarily driven by higher net revenues in the smokeable products segment. Revenues net of excise taxes increased 3.6% to $5.4 billion.
  • Reported diluted EPS increased 7.1% to $1.51, primarily driven by higher reported operating companies income (OCI) and higher reported earnings from our investment in ABI.
  • Adjusted diluted EPS increased 4.8% to $1.52, primarily driven by higher adjusted OCI and higher adjusted earnings from our investment in ABI.

First Nine Months

  • Net revenues increased 1.4% to $17.7 billion, primarily driven by higher net revenues in the smokeable products segment. Revenues net of excise taxes increased 3.3% to $15.6 billion.
  • Reported diluted EPS increased 21.2% to $4.18, primarily driven by higher reported OCI, which includes a 2025 non-cash impairment of the e-vapor reporting unit goodwill.
  • Adjusted diluted EPS increased 5.1% to $4.33, primarily driven by higher adjusted OCI, fewer shares outstanding and higher adjusted earnings from our investment in ABI.
Table 1 - Altria’s Adjusted Results
Third Quarter Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
Reported diluted EPS $ 1.51 $ 1.41 7.1 % $ 4.18 $ 3.45 21.2 %
Acquisition-related items — — — 0.05
Asset impairment, exit and implementation costs — — 0.05 0.53
Tobacco and health and certain other litigation items 0.01 — 0.05 0.02
Amortization of intangibles 0.01 0.02 0.04 0.05
ABI-related special items (0.02 ) 0.02 0.02 0.02
Cronos-related special items — 0.01 — —
Income tax items 0.01 (0.01 ) (0.01 ) —
Adjusted diluted EPS $ 1.52 $ 1.45 4.8 % $ 4.33 $ 4.12 5.1 %

Note: For details of pre-tax, tax and after-tax amounts, see Schedule 6, 7, 8 & 9.

Special Items

The EPS impact of the following special items is shown in Table 1 and Schedules 6, 7, 8 and 9.

Acquisition-Related Items

In the first nine months of 2025, we recorded net pre-tax expense items of $96 million (or $0.05 per share), including $71 million related to the U.S. International Trade Commission’s exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, partially offset by insurance recoveries from insurance contracts associated with the acquisition of NJOY. Also included was a $25 million non-cash, pre-tax charge related to a change in the fair value of contingent payments associated with the acquisition of NJOY.

Asset Impairment, Exit and Implementation Costs

In the first nine months of 2026, we recorded pre-tax charges of $106 million (or $0.05 per share), primarily due to our plans to consolidate USSTC’s manufacturing operations (USSTC Facilities Consolidation).

In the first nine months of 2025, we recorded pre-tax charges of $916 million (or $0.53 per share), primarily due to a non-cash impairment charge of $873 million to the e-vapor reporting unit goodwill in our all other category.

Tobacco and Health and Certain Other Litigation Items

In the first nine months of 2026, we recorded pre-tax charges of $120 million (or $0.05 per share) for tobacco and health and certain other litigation items and related interest costs.

In the first nine months of 2025, we recorded pre-tax charges of $48 million (or $0.02 per share) for tobacco and health and certain other litigation items and related interest costs.

Amortization of Intangibles

In the first nine months of 2026, we recorded pre-tax amortization of intangibles of $67 million (or $0.04 per share).

In the third quarter and first nine months of 2025, we recorded pre-tax amortization of intangibles of $38 million (or $0.02 per share) and $112 million (or $0.05 per share), respectively.

ABI-Related Special Items

In the third quarter of 2026, we recorded net pre-tax income of $37 million (or $0.02 per share), primarily due to mark-to-market gains on certain ABI financial instruments associated with its share commitments. In the first nine months of 2026, we recorded net pre-tax losses of $41 million (or $0.02 per share), primarily due to a dilution loss resulting from ABI’s share activity that reduced our ABI ownership interest, partially offset by mark-to-market gains on certain ABI financial instruments associated with its share commitments.

In the third quarter and first nine months of 2025, we recorded net pre-tax losses of $34 million (or $0.02 per share) and $36 million (or $0.02 per share), respectively, for ABI-related special items, primarily related to mark-to-market losses on certain ABI financial instruments associated with its share commitments.

The ABI-related special items include our respective share of the amounts recorded by ABI and additional adjustments related to (i) the conversion of ABI-related special items from international financial reporting standards to GAAP and (ii) adjustments to our investment required under the equity method of accounting.

SMOKEABLE PRODUCTS

Revenues and OCI

Third Quarter

  • Net revenues increased 0.8%, primarily driven by higher pricing, partially offset by higher promotional investments, lower shipment volume and a higher percentage of discount shipment volume relative to premium versus the prior year (volume mix change). Revenues net of excise taxes increased 3.7%.
  • Reported and adjusted OCI increased 3.8% and 3.9%, respectively, primarily driven by higher pricing and higher refunds of taxes and duties paid on imported cigarettes, partially offset by higher promotional investments, lower shipment volume, volume mix change and higher costs (primarily manufacturing). Adjusted OCI margins increased by 0.1 percentage point to 64.5%.

First Nine Months

  • Net revenues increased 1.4%, primarily driven by higher pricing, partially offset by higher promotional investments, lower shipment volume and volume mix change. Revenues net of excise taxes increased 3.6%.
  • Reported OCI increased 3.9%, primarily driven by higher pricing and higher refunds of taxes and duties paid on imported cigarettes, partially offset by higher promotional investments, lower shipment volume, volume mix change, higher manufacturing costs and higher tobacco and health and certain other litigation items.
  • Adjusted OCI increased 4.1%, primarily driven by higher pricing and higher refunds of taxes and duties paid on imported cigarettes, partially offset by higher promotional investments, lower shipment volume, volume mix change and higher manufacturing costs. Adjusted OCI margins increased by 0.4 percentage points to 64.8%.
Table 2 - Smokeable Products: Revenues and OCI ($ in millions)
Third Quarter Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
Net revenues $ 5,432 $ 5,387 0.8 % $ 15,582 $ 15,366 1.4 %
Excise taxes (670 ) (797 ) (2,050 ) (2,299 )
Revenues net of excise taxes $ 4,762 $ 4,590 3.7 % $ 13,532 $ 13,067 3.6 %
Reported OCI $ 3,053 $ 2,942 3.8 % $ 8,668 $ 8,341 3.9 %
NPM Adjustment Items — (2 ) (4 ) (2 )
Asset impairment, exit and implementation costs 3 12 17 38
Tobacco and health and certain other litigation items 16 4 85 44
Adjusted OCI $ 3,072 $ 2,956 3.9 % $ 8,766 $ 8,421 4.1 %
Reported OCI margins1 64.1 % 64.1 % 0.0 pp 64.1 % 63.8 % 0.3 pp
Adjusted OCI margins1 64.5 % 64.4 % 0.1 pp 64.8 % 64.4 % 0.4 pp

1 Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

  • Smokeable products segment reported domestic cigarette shipment volume decreased 2.9%, primarily driven by the industry’s decline rate, partially offset by trade inventory movements and retail share gains.
  • When adjusted for trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 4%.
  • When adjusted for trade inventory movements, total domestic cigarette industry volume decreased by an estimated 5%.
  • Reported cigar shipment volume increased 0.9%.

First Nine Months

  • Smokeable products segment reported domestic cigarette shipment volume decreased 2.8%, primarily driven by the industry’s decline rate, partially offset by trade inventory movements and retail share gains.
  • When adjusted for trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 4%.
  • When adjusted for trade inventory movements, total domestic cigarette industry volume decreased by an estimated 5%.
  • Reported cigar shipment volume increased 2.0%.
Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)
Third Quarter Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
Cigarettes:
Marlboro 13,324 14,235 (6.4 )% 38,673 41,671 (7.2 )%
Other premium 697 744 (6.3 )% 1,976 2,141 (7.7 )%
Discount 1,704 1,213 40.5 % 4,497 2,650 69.7 %
Total domestic cigarettes1 15,725 16,192 (2.9 )% 45,146 46,462 (2.8 )%
Cigars:
Black & Mild 456 452 0.9 % 1,362 1,335 2.0 %
Other 1 1 — % 2 2 — %
Total cigars 457 453 0.9 % 1,364 1,337 2.0 %
Total domestic smokeable products 16,182 16,645 (2.8 )% 46,510 47,799 (2.7 )%
Contract manufactured export cigarettes2 1,595 311 100%+ 2,941 786 100%+

1 Domestic cigarettes shipment volume includes Marlboro; Other premium brands, such as Virginia Slims and Parliament; and Discount brands, which include L&M and Basic. Domestic cigarettes volume includes units sold as well as promotional units sold for distribution in the U.S. and excludes units sold for distribution to Puerto Rico, U.S. Territories to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to our smokeable products segment.

2 Contract manufactured export cigarettes shipment volume represents contract manufactured cigarettes for third parties that market and sell tobacco products outside the U.S.

Retail Share and Brand Activity

Third Quarter

  • Marlboro retail share of the total cigarette category was 39.5%, a decrease of 1.0 share point versus the prior year and unchanged sequentially. Marlboro share of the premium segment was 60.0%, an increase of 0.3 share points versus the prior year and 0.4 share points sequentially.
  • The cigarette industry discount retail share was 34.1%, an increase of 2.0 share points versus the prior year and 0.3 share points sequentially, primarily due to continued discretionary income pressures on adult smokers.

First Nine Months

  • Marlboro retail share of the total cigarette category was 39.5%, a decrease of 1.4 share points. Marlboro share of the premium segment was 59.7%, an increase of 0.1 share point versus the prior year.
  • The cigarette industry discount retail share was 33.8%, an increase of 2.4 share points, primarily due to continued discretionary income pressures on adult smokers.
Table 4 - Smokeable Products: Domestic Cigarettes Retail Share (percent)
Third Quarter Nine Months Ended September 30,
2026 2025 Percentage point change 2026 2025 Percentage point change
Cigarettes:
Marlboro 39.5% 40.5% (1.0) 39.5% 40.9% (1.4)
Other premium 2.1 2.2 (0.1) 2.1 2.2 (0.1)
Discount 4.1 2.7 1.4 4.0 2.1 1.9
Total cigarettes 45.7% 45.4% 0.3 45.6% 45.2% 0.4

Note: Retail share results for cigarettes are based on data from Circana, LLC (Circana) as well as MSAi. Circana maintains a blended retail service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (STARS), as provided by MSAi. This service is not designed to capture sales through other channels, including the internet, direct mail and some tax-advantaged outlets. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

ORAL TOBACCO PRODUCTS

Revenues and OCI

Third Quarter

  • Net revenues decreased 0.1%, as lower shipment volume and higher promotional investments mostly offset higher pricing. Revenues net of excise taxes increased 0.3%.
  • Reported OCI decreased 5.4%, primarily driven by lower shipment volume, higher costs, which include 2026 costs related to the USSTC Facilities Consolidation, and higher promotional investments, partially offset by higher pricing.
  • Adjusted OCI decreased 3.7%, primarily driven by lower shipment volume, higher costs and higher promotional investments, partially offset by higher pricing. Adjusted OCI margins decreased 2.8 percentage points to 66.4%.

First Nine Months

  • Net revenues decreased 1.2%, primarily driven by lower shipment volume and higher promotional investments, partially offset by higher pricing. Revenues net of excise taxes decreased 0.9%.
  • Reported OCI decreased 10.1%, primarily driven by lower shipment volume, higher costs, which include 2026 costs related to the USSTC Facilities Consolidation, and higher promotional investments, partially offset by higher pricing.
  • Adjusted OCI decreased 4.0%, primarily driven by lower shipment volume, higher promotional investments and higher costs, partially offset by higher pricing. Adjusted OCI margins decreased 2.2 percentage points to 66.8%.
Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)
Third Quarter Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
Net revenues $ 688 $ 689 (0.1 )% $ 2,070 $ 2,096 (1.2 )%
Excise taxes (21 ) (24 ) (66 ) (74 )
Revenues net of excise taxes $ 667 $ 665 0.3 % $ 2,004 $ 2,022 (0.9 )%
Reported OCI $ 434 $ 459 (5.4 )% $ 1,250 $ 1,390 (10.1 )%
Asset impairment, exit and implementation costs 9 1 89 5
Adjusted OCI $ 443 $ 460 (3.7 )% $ 1,339 $ 1,395 (4.0 )%
Reported OCI margins1 65.1 % 69.0 % (3.9) pp 62.4 % 68.7 % (6.3) pp
Adjusted OCI margins1 66.4 % 69.2 % (2.8) pp 66.8 % 69.0 % (2.2) pp

1 Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

  • Oral tobacco products segment reported domestic shipment volume decreased 4.3%, primarily driven by retail share losses and other factors, partially offset by the industry’s growth rate and trade inventory movements.
  • When adjusted for trade inventory movements, oral tobacco products segment domestic shipment volume decreased by an estimated 5%.

First Nine Months

  • Oral tobacco products segment reported domestic shipment volume decreased 5.4%, primarily driven by retail share losses and trade inventory movements, partially offset by the industry’s growth rate and other factors.
  • When adjusted for trade inventory movements, oral tobacco products segment domestic shipment volume decreased by an estimated 5%.
  • Total oral industry volume increased by an estimated 5.5% for the six months ended September 30, 2026, primarily driven by growth in oral nicotine pouches, partially offset by declines in moist smokeless tobacco (MST).
Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans in millions)
Third Quarter Nine Months Ended September 30,
2026 2025 Change 2026 2025 Change
Copenhagen 79.8 88.8 (10.1 )% 245.6 274.4 (10.5 )%
Skoal 27.1 31.0 (12.6 )% 84.5 96.6 (12.5 )%
on! 47.8 42.2 13.3 % 143.9 133.6 7.7 %
Other 15.9 16.2 (1.9 )% 48.2 47.6 1.3 %
Total oral tobacco products 170.6 178.2 (4.3 )% 522.2 552.2 (5.4 )%

Note: Volume includes cans sold, as well as promotional units, but excludes non-domestic volume, which is currently not material to our oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans shipped, one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST.

Retail Share and Brand Activity

Third Quarter

  • on! retail share of the oral tobacco category was 8.3%, an increase of 0.1 share point versus the prior year and down 0.3 share points sequentially.
  • The nicotine pouch category was 61.2% of the oral tobacco category, an increase of 5.8 share points versus the prior year and 1.3 share points sequentially. on! retail share of the nicotine pouch category was 13.5%, a decrease of 1.3 share points versus the prior year and a decrease of 0.9 share points sequentially.

First Nine Months

  • on! retail share of the U.S. oral tobacco category was 8.2%, a decrease of 0.2 share points.
  • The nicotine pouch category was 59.8% of the oral tobacco category, an increase of 7.6 share points. on! retail share of the nicotine pouch category was 13.8%, a decrease of 2.3 share points.
Table 7 - Oral Tobacco Products: Retail Share (percent)
Third Quarter Nine Months Ended September 30,
2026 2025 Percentage point change 2026 2025 Percentage point change
Copenhagen 12.6% 14.6% (2.0) 13.1% 15.7% (2.6)
Skoal 4.8 5.5 (0.7) 5.1 6.0 (0.9)
on! 8.3 8.2 0.1 8.2 8.4 (0.2)
Other 2.2 2.3 (0.1) 2.2 2.4 (0.2)
Total oral tobacco products 27.9% 30.6% (2.7) 28.6% 32.5% (3.9)

Note: Our oral tobacco products segment’s retail share results exclude non-domestic volume, which is currently not material to our oral tobacco products segment. Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans sold. Oral tobacco products are defined by Circana as domestic oral products, in the form of MST and oral nicotine pouch products (inclusive of tobacco-derived and synthetic oral nicotine products). New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example, one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

Altria’s Profile

We are a leader in nicotine with a growing portfolio of products for adult nicotine consumers age 21+. Today, we are focused on elevating everyday moments by offering adult nicotine consumers a range of product choices and the information they need to make informed decisions. All adult nicotine consumers deserve clear and accurate information – whether they continue using nicotine, switch from cigarettes to regulated smoke-free alternatives, or quit entirely.

We are Moving Beyond Smoking® by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers and exploring new growth opportunities – beyond the United States and beyond nicotine (Vision). Guided by innovation, science and responsible business practices, we are committed to creating long-term value for Altria, our stakeholders and society.

For decades, we have led the nicotine industry in advocating for science-based regulation and accountability. Our more than 5,000 employees across the U.S. advance that work in partnership with thousands of companies across our value chain.

Our American roots stretch back more than 200 years, and our operating companies’ brands have served adult nicotine consumers for generations. The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Our wholly owned subsidiaries include Philip Morris USA Inc. (PM USA), John Middleton Co. (Middleton), U.S. Smokeless Tobacco Company LLC (USSTC), Helix Innovations LLC (Helix) and NJOY, LLC (NJOY).

We also have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products. Our investments in equity securities include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

Basis of Presentation

We report our financial results in accordance with GAAP. Our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments. Our management also reviews certain financial results, including OCI, OCI margins and diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under “2026 Full-Year Guidance.” Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management also reviews income tax rates on an adjusted basis. Our adjusted effective tax rate may exclude certain items from our reported effective tax rate. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating capital and other resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with, GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. We provide reconciliations of historical adjusted financial measures to corresponding GAAP measures in this release.

We use the equity method of accounting for our investments in ABI and Cronos and report our share of ABI’s and Cronos’s results using a one-quarter lag because ABI’s and Cronos’s results are not available in time for us to record them in the concurrent period. The one-quarter reporting lag for ABI and Cronos does not affect our cash flows.

Our reportable segments are (i) smokeable products, consisting of combustible cigarettes and machine-made large cigars, and (ii) oral tobacco products, consisting of MST and oral nicotine pouches. We have included results for NJOY, Horizon, Helix International and other business activities, which primarily consists of research and development expense related to certain new product platforms and technologies, in “All Other.” Comparisons are to the corresponding prior-year period unless otherwise stated.

Forward-Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Share repurchases depend on marketplace conditions and other factors. In addition, future dividend payments and share repurchases remain subject to the discretion of our Board of Directors.

Important factors that could cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2025. These factors and risks include the following:

  • our inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior;
  • our inability to compete effectively;
  • the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;
  • the impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products, each of which contribute to reductions in the consumption levels and shipment volumes of our operating companies’ products;
  • our failure to develop and commercialize innovative products, including nicotine products that may reduce health risks relative to other nicotine products and appeal to adult nicotine consumers;
  • changes, including in macroeconomic and geopolitical conditions (including inflation, tariffs and the economic impacts of international armed conflicts), that result in shifts in adult nicotine consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;
  • unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;
  • the risks associated with significant federal, state and local government actions, including U.S. Food and Drug Administration (FDA) regulatory actions and inaction, and various private sector actions;
  • the risk that regulators, including the FDA, and courts may interpret laws, rules and regulations applicable to our operating companies’ products differently than we do;
  • increases in nicotine product-related taxes;
  • our failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships and investments in third parties, or realize the anticipated benefits of such transactions;
  • significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, geopolitical, climate and environmental conditions;
  • our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;
  • the risk that we may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment;
  • the risks associated with our Initiative, including risks relating to business continuity, our internal control over financial reporting and audit procedures and our ability to recognize the expected efficiencies;
  • the risk that we could decide, or be required, to recall products;
  • the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;
  • our inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;
  • the compliance risks associated with our expanded international business activities and the related complexity of U.S. and foreign laws and regulations applicable to those activities;
  • the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;
  • the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;
  • disruption and uncertainty in the credit and capital markets, including the risk of losing access to these markets;
  • a downgrade or potential downgrade of our credit ratings;
  • the impact of heightened focus by investors and other stakeholders on our performance relating to corporate responsibility matters;
  • the failure of our, or our key service providers’ or key suppliers’, information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;
  • our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;
  • the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all; and
  • the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Schedule 1
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
2026 2025 % Change
Net revenues $ 6,132 $ 6,072 1.0 %
Cost of sales1 1,500 1,439
Excise taxes on products1 691 821
Gross profit 3,941 3,812 3.4 %
Marketing, administration and research costs 539 485
Exit costs 3 2
Operating companies income 3,399 3,325 2.2 %
Amortization of intangibles 21 38
General corporate expenses 65 57
Operating income 3,313 3,230 2.6 %
Interest and other debt expense, net 270 278
Net periodic benefit income, excluding service cost (5 ) (16 )
(Income) losses from investments in equity securities1 (242 ) (107 )
Earnings before income taxes 3,290 3,075 7.0 %
Provision for income taxes 776 700
Net earnings 2,514 2,375 5.9 %
Net losses attributable to noncontrolling interest 4 —
Net earnings attributable to Altria $ 2,518 $ 2,375 6.0 %
Per share data:
Diluted earnings per share $ 1.51 $ 1.41 7.1 %
Weighted-average diluted shares outstanding 1,669 1,680 (0.7 )%
1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.
Schedule 2
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Quarters Ended September 30,
(dollars in millions)
(Unaudited)
Net Revenues
Smokeable Products Oral Tobacco Products All Other Total
2026 $ 5,432 $ 688 $ 12 $ 6,132
2025 5,387 689 (4 ) 6,072
% Change 0.8 % (0.1 )% 100%+ 1.0 %
Reconciliation:
For the quarter ended September 30, 2025 $ 5,387 $ 689 $ (4 ) $ 6,072
Operations 45 (1 ) 16 60
For the quarter ended September 30, 2026 $ 5,432 $ 688 $ 12 $ 6,132
Operating Companies Income (Loss)
Smokeable Products Oral Tobacco Products All Other Total
2026 $ 3,053 $ 434 $ (88 ) $ 3,399
2025 2,942 459 (76 ) 3,325
% Change 3.8 % (5.4 )% (15.8 )% 2.2 %
Reconciliation:
For the quarter ended September 30, 2025 $ 2,942 $ 459 $ (76 ) $ 3,325
NPM Adjustment Items - 2025 (2 ) — — (2 )
Asset impairment, exit and implementation costs - 2025 12 1 — 13
Tobacco and health and certain other litigation items - 2025 4 — — 4
14 1 — 15
Asset impairment, exit and implementation costs - 2026 (3 ) (9 ) — (12 )
Tobacco and health and certain other litigation items - 2026 (16 ) — — (16 )
(19 ) (9 ) — (28 )
Operations 116 (17 ) (12 ) 87
For the quarter ended September 30, 2026 $ 3,053 $ 434 $ (88 ) $ 3,399
Schedule 3
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
2026 2025 % Change
Net revenues $ 17,671 $ 17,433 1.4 %
Cost of sales1 4,288 4,149
Excise taxes on products 1 2,116 2,373
Gross profit 11,267 10,911 3.3 %
Marketing, administration and research costs 1,566 1,502
Exit costs 24 3
Impairment of goodwill — 873
Operating companies income 9,677 8,533 13.4 %
Amortization of intangibles 67 112
General corporate expenses 205 173
Operating income 9,405 8,248 14.0 %
Interest and other debt expense, net 823 815
Net periodic benefit income, excluding service cost (9 ) (45 )
(Income) losses from investments in equity securities1 (487 ) (398 )
Earnings before income taxes 9,078 7,876 15.3 %
Provision for income taxes 2,083 2,046
Net earnings 6,995 5,830 20.0 %
Net losses attributable to noncontrolling interest 4 —
Net earnings attributable to Altria $ 6,999 $ 5,830 20.1 %
Per share data2:
Diluted earnings per share $ 4.18 $ 3.45 21.2 %
Weighted-average diluted shares outstanding 1,671 1,685 (0.8 )%
1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.
2 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
Schedule 4
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Nine Months Ended September 30,
(dollars in millions)
(Unaudited)
Net Revenues
Smokeable Products Oral Tobacco Products All Other Total
2026 $ 15,582 $ 2,070 $ 19 $ 17,671
2025 15,366 2,096 (29 ) 17,433
% Change 1.4 % (1.2 )% 100%+ 1.4 %
Reconciliation:
For the nine months ended September 30, 2025 $ 15,366 $ 2,096 $ (29 ) $ 17,433
Acquisition-related items - 2025 — — 42 42
Operations 216 (26 ) 6 196
For the nine months ended September 30, 2026 $ 15,582 $ 2,070 $ 19 $ 17,671
Operating Companies Income (Loss)
Smokeable Products Oral Tobacco Products All Other Total
2026 $ 8,668 $ 1,250 $ (241 ) $ 9,677
2025 8,341 1,390 (1,198 ) 8,533
% Change 3.9 % (10.1 )% 79.9 % 13.4 %
Reconciliation:
For the nine months ended September 30, 2025 $ 8,341 $ 1,390 $ (1,198 ) $ 8,533
NPM Adjustment Items - 2025 (2 ) — — (2 )
Acquisition-related items - 2025 — — 86 86
Asset impairment, exit and implementation costs - 2025 38 5 873 916
Tobacco and health and certain other litigation items - 2025 44 — — 44
80 5 959 1,044
NPM Adjustment Items - 2026 4 — — 4
Asset impairment, exit and implementation costs - 2026 (17 ) (89 ) — (106 )
Tobacco and health and certain other litigation items - 2026 (85 ) — — (85 )
(98 ) (89 ) — (187 )
Operations 345 (56 ) (2 ) 287
For the nine months ended September 30, 2026 $ 8,668 $ 1,250 $ (241 ) $ 9,677
Schedule 5
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data
(dollars in millions)
(Unaudited)
For the Quarters Ended September 30, For the Nine Months Ended September 30,
2026 2025 2026 2025
The segment detail of excise taxes on products sold is as follows:
Smokeable products $ 670 $ 797 $ 2,050 $ 2,299
Oral tobacco products 21 24 66 74
$ 691 $ 821 $ 2,116 $ 2,373
The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows:
Smokeable products $ 775 $ 792 $ 2,228 $ 2,278
$ 775 $ 792 $ 2,228 $ 2,278
The segment detail of FDA user fees included in cost of sales is as follows:
Smokeable products $ 60 $ 64 $ 187 $ 184
Oral tobacco products 1 2 4 4
$ 61 $ 66 $ 191 $ 188
The detail of (income) losses from investments in equity securities is as follows:
ABI $ (228 ) $ (123 ) $ (468 ) $ (396 )
Cronos (14 ) 16 (19 ) (2 )
$ (242 ) $ (107 ) $ (487 ) $ (398 )
Schedule 6
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings Attributable to Altria Group, Inc. and Diluted Earnings Per Share
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
Net Earnings Attributable to Altria Diluted EPS
2026 $ 2,518 $ 1.51
2025 $ 2,375 $ 1.41
% Change 6.0 % 7.1 %
Reconciliation:
2025 $ 2,375 $ 1.41
2025 NPM Adjustment Items (2 ) —
2025 Acquisition-related items 3 —
2025 Asset impairment, exit and implementation costs 10 —
2025 Tobacco and health and certain other litigation items 3 —
2025 Amortization of intangibles 30 0.02
2025 ABI-related special items 27 0.02
2025 Cronos-related special items 18 0.01
2025 Income tax items (20 ) (0.01 )
Subtotal 2025 special items 69 0.04
2026 Asset impairment, exit and implementation costs (8 ) —
2026 Tobacco and health and certain other litigation items (17 ) (0.01 )
2026 Amortization of intangibles (18 ) (0.01 )
2026 ABI-related special items 27 0.02
2026 Cronos-related special items 6 —
2026 Income tax items (19 ) (0.01 )
Subtotal 2026 special items (29 ) (0.01 )
Fewer shares outstanding — 0.01
Change in tax rate 6 —
Operations 97 0.06
2026 $ 2,518 $ 1.51
Schedule 7
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
Earnings before Income Taxes Provision for Income Taxes Net Earnings Attributable to Altria Diluted EPS
2026 Reported $ 3,290 $ 776 $ 2,518 $ 1.51
Acquisition-related items (1 ) (1 ) — —
Asset impairment, exit and implementation costs 12 4 8 —
Tobacco and health and certain other litigation items 23 6 17 0.01
Amortization of intangibles 21 3 18 0.01
ABI-related special items (37 ) (10 ) (27 ) (0.02 )
Cronos-related special items (7 ) (1 ) (6 ) —
Income tax items — (19 ) 19 0.01
2026 Adjusted for Special Items $ 3,301 $ 758 $ 2,547 $ 1.52
2025 Reported $ 3,075 $ 700 $ 2,375 $ 1.41
NPM Adjustment Items (2 ) — (2 ) —
Acquisition-related items 1 (2 ) 3 —
Asset impairment, exit and implementation costs 13 3 10 —
Tobacco and health and certain other litigation items 3 — 3 —
Amortization of intangibles 38 8 30 0.02
ABI-related special items 34 7 27 0.02
Cronos-related special items 18 — 18 0.01
Income tax items — 20 (20 ) (0.01 )
2025 Adjusted for Special Items $ 3,180 $ 736 $ 2,444 $ 1.45
2026 Reported Net Earnings Attributable to Altria and Reported Diluted EPS $ 2,518 $ 1.51
2025 Reported Net Earnings Attributable to Altria and Reported Diluted EPS $ 2,375 $ 1.41
% Change 6.0 % 7.1 %
2026 Adjusted Net Earnings Attributable to Altria and Adjusted Diluted EPS $ 2,547 $ 1.52
2025 Adjusted Net Earnings Attributable to Altria and Adjusted Diluted EPS $ 2,444 $ 1.45
% Change 4.2 % 4.8 %
Reported1 Adjusted2
2026 Effective Tax Rate 23.6 % 23.0 %
2025 Effective Tax Rate 22.8 % 23.1 %
Change 0.8 pp (0.1) pp
1 Reported effective tax rate is calculated as reported provision for income taxes divided by reported earnings before income taxes provided above.
2 Adjusted effective tax rate is calculated as provision for income taxes adjusted for special items divided by earnings before income taxes adjusted for special items provided above.
Schedule 8
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings Attributable to Altria Group, Inc. and Diluted Earnings Per Share
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
Net Earnings Attributable to Altria Diluted EPS1
2026 $ 6,999 $ 4.18
2025 $ 5,830 $ 3.45
% Change 20.1 % 21.2 %
Reconciliation:
2025 $ 5,830 $ 3.45
2025 NPM Adjustment Items (2 ) —
2025 Acquisition-related items 80 0.05
2025 Asset impairment, exit and implementation costs 906 0.53
2025 Tobacco and health and certain other litigation items 37 0.02
2025 Amortization of intangibles 92 0.05
2025 ABI-related special items 28 0.02
2025 Cronos-related special items 2 —
2025 Income tax items (7 ) —
Subtotal 2025 special items 1,136 0.67
2026 NPM Adjustment Items 9 —
2026 Acquisition-related items (10 ) —
2026 Asset impairment, exit and implementation costs (80 ) (0.05 )
2026 Tobacco and health and certain other litigation items (91 ) (0.05 )
2026 Amortization of intangibles (60 ) (0.04 )
2026 ABI-related special items (33 ) (0.02 )
2026 Cronos-related special items 8 —
2026 Income tax items 11 0.01
Subtotal 2026 special items (246 ) (0.15 )
Fewer shares outstanding — 0.04
Change in tax rate 29 0.02
Operations 250 0.15
2026 $ 6,999 $ 4.18
1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
Schedule 9
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)
Earnings before Income Taxes Provision for Income Taxes Net Earnings Attributable to Altria Diluted EPS1
2026 Reported $ 9,078 $ 2,083 $ 6,999 $ 4.18
NPM Adjustment Items (11 ) (2 ) (9 ) —
Acquisition-related items 13 3 10 —
Asset impairment, exit and implementation costs 106 26 80 0.05
Tobacco and health and certain other litigation items 120 29 91 0.05
Amortization of intangibles 67 7 60 0.04
ABI-related special items 41 8 33 0.02
Cronos-related special items (9 ) (1 ) (8 ) —
Income tax items — 11 (11 ) (0.01 )
2026 Adjusted for Special Items $ 9,405 $ 2,164 $ 7,245 $ 4.33
2025 Reported $ 7,876 $ 2,046 $ 5,830 $ 3.45
NPM Adjustment Items (2 ) — (2 ) —
Acquisition-related items 96 16 80 0.05
Asset impairment, exit and implementation costs 916 10 906 0.53
Tobacco and health and certain other litigation items 48 11 37 0.02
Amortization of intangibles 112 20 92 0.05
ABI-related special items 36 8 28 0.02
Cronos-related special items 2 — 2 —
Income tax items — 7 (7 ) —
2025 Adjusted for Special Items $ 9,084 $ 2,118 $ 6,966 $ 4.12
2026 Reported Net Earnings Attributable to Altria and Reported Diluted EPS $ 6,999 $ 4.18
2025 Reported Net Earnings Attributable to Altria and Reported Diluted EPS $ 5,830 $ 3.45
% Change 20.1 % 21.2 %
2026 Adjusted Net Earnings Attributable to Altria and Adjusted Diluted EPS $ 7,245 $ 4.33
2025 Adjusted Net Earnings Attributable to Altria and Adjusted Diluted EPS $ 6,966 $ 4.12
% Change 4.0 % 5.1 %
Reported2 Adjusted3
2026 Effective Tax Rate 22.9 % 23.0 %
2025 Effective Tax Rate 26.0 % 23.3 %
Change (3.1) pp (0.3) pp
1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
2 Reported effective tax rate is calculated as reported provision for income taxes divided by reported earnings before income taxes provided above.
3 Adjusted effective tax rate is calculated as provision for income taxes adjusted for special items divided by earnings before income taxes adjusted for special items provided above.
Schedule 10
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Year Ended December 31, 2025
(dollars in millions, except per share data)
(Unaudited)
Earnings before Income Taxes Provision for Income Taxes Net Earnings Attributable to Altria Diluted EPS
2025 Reported $ 9,389 $ 2,442 $ 6,947 $ 4.12
NPM Adjustment Items (20 ) (5 ) (15 ) (0.01 )
Acquisition-related items 76 10 66 0.04
Asset impairment, exit and implementation costs 2,184 263 1,921 1.14
Tobacco and health and certain other litigation items 58 14 44 0.03
Amortization of intangibles 132 22 110 0.06
ABI-related special items 95 20 75 0.04
Cronos-related special items (5 ) — (5 ) —
Income tax items — (5 ) 5 —
2025 Adjusted for Special Items $ 11,909 $ 2,761 $ 9,148 $ 5.42
Schedule 11
ALTRIA GROUP, INC.
and Subsidiaries
Condensed Consolidated Balance Sheets
(dollars in millions)
(Unaudited)
September 30, 2026 December 31, 2025
Assets
Cash and cash equivalents $ 2,697 $ 4,474
Inventories 1,084 1,070
Other current assets 1,017 388
Property, plant and equipment, net 1,669 1,710
Goodwill and other intangible assets, net 17,616 17,663
Investments in equity securities 9,326 8,617
Other long-term assets 1,069 1,095
Total assets $ 34,478 $ 35,017
Liabilities and Stockholders’ Equity (Deficit)
Current portion of long-term debt $ 1,175 $ 1,569
Accrued settlement charges 1,942 2,178
Other current liabilities 5,173 5,407
Long-term debt 22,886 24,140
Deferred income taxes 3,577 3,370
Accrued pension costs 116 122
Accrued postretirement health care costs 942 939
Other long-term liabilities 840 744
Total liabilities 36,651 38,469
Total stockholders’ equity (deficit) attributable to Altria (2,225 ) (3,502 )
Noncontrolling interest 52 50
Total liabilities and stockholders’ equity (deficit) $ 34,478 $ 35,017
Total debt $ 24,061 $ 25,709
Schedule 12
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Quarters Ended September 30,
(dollars in millions)
(Unaudited)
**Cost of **Sales **Marketing, ****administration **and research costs Exit costs Amortization of intangibles **General ****corporate **expenses Interest and other debt (income) expense, net **(Income) losses from **investments in equity securities
2026 Special Items - (Income) Expense
Acquisition-related items $ — $ — $ — $ — $ (1 ) $ — $ —
Asset impairment, exit and implementation costs 7 2 3 — — — —
Tobacco and health and certain other litigation items — 16 — — — 7 —
Amortization of intangibles — — — 21 — — —
ABI-related special items — — — — — — (37 )
Cronos-related special items — — — — — — (7 )
2025 Special Items - (Income) Expense
NPM Adjustment Items $ (2 ) $ — $ — $ — $ — $ — $ —
Acquisition-related items — — — — 1 — —
Asset impairment, exit and implementation costs — 11 2 — — — —
Tobacco and health and certain other litigation items — 4 — — (1 ) — —
Amortization of intangibles — — — 38 — — —
ABI-related special items — — — — — — 34
Cronos-related special items — — — — — — 18

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

Schedule 13
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Nine Months Ended September 30,
(dollars in millions)
(Unaudited)
Net Revenues **Cost of **Sales Marketing, administration and research costs Exit costs Impairment of goodwill Amortization of intangibles General corporate expenses Interest and other debt (income) expense, net **(Income) losses from **investments in equity securities
2026 Special Items - (Income) Expense
NPM Adjustment Items $ — $ (4 ) $ — $ — $ — $ — $ — $ (7 ) $ —
Acquisition-related items — — — — — — 13 — —
Asset impairment, exit and implementation costs — 66 16 24 — — — — —
Tobacco and health and certain other litigation items — — 85 — — — 4 31 —
Amortization of intangibles — — — — — 67 — — —
ABI-related special items — — — — — — — — 41
Cronos-related special items — — — — — — — — (9 )
2025 Special Items - (Income) Expense
NPM Adjustment Items $ — $ (2 ) $ — $ — $ — $ — $ — $ — $ —
Acquisition-related items 42 44 — — — — 10 — —
Asset impairment, exit and implementation costs — — 40 3 873 — — — —
Tobacco and health and certain other litigation items — — 44 — — — — 4 —
Amortization of intangibles — — — — — 112 — — —
ABI-related special items — — — — — — (1 ) — 37
Cronos-related special items — — — — — — — — 2

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

Mac Livingston, Vice President of Investor Relations
[email protected]

Altria Client Services
Investor Relations
(804) 484-8222

Altria Client Services
Media Relations
www.altria.com/contact-us/media

Source: Altria Group, Inc.

10/23/2026

Download this Press Release PDF Format (opens in new window)

Paige Spiranac and Team Grass League claimed golf’s orangest jacket following a dramatic comeback victory, with Flo Rida bringing the two-day event to an electrifying close with a hit-filled performance

RICHMOND, Va.--(BUSINESS WIRE)-- Helix Innovations LLC, an operating company of Altria Group, Inc. (Altria) (NYSE: MO), today announced the winners of on!® nicotine pouches’ inaugural on!vitational, held October 16 and 17 at TGL’s SoFi Center in Palm Beach Gardens, Florida. The two-day golf and entertainment experience brought together eight teams of current and former professional athletes, golf personalities, entertainers and adult nicotine consumers age 25+ for a competition that combined golf, technology and entertainment.

Well-known golf influencer Paige Spiranac and Team Grass League, including former professional golfer Drew Kittleson and Grass League co-founder Jimmy Hoselton, captured the inaugural on!vitational Championship. The team defeated former PGA TOUR veteran Ricky Barnes and Team Troon in a dramatic final to claim the tournament trophy and golf’s orangest jacket. After teams including Malbon, Palm Tree Crew and Hypegolf battled throughout the competition, Grass League staged a thrilling comeback, with an on!® consumer sweepstakes winner delivering a pivotal shot on the penultimate hole to help secure the victory.

Unlike traditional golf tournaments, the on!vitational put nicotine consumers 25+ directly into the competition alongside some of the biggest personalities in golf, sports and entertainment. Consumer participants, selected at random through an on!® sweepstakes earlier this year, competed as members of the eight teams. The two-day event was emceed by popular golf influencer and TGL host Roger Steele.

Grass League co-founder Jimmy Hoselton summed up the excitement: “on!® has been with us from the beginning. We're all in on on!®, and we're all in on the on!vitational.”

A New Kind of Golf Competition

Held inside TGL’s 250,000-square-foot SoFi Center, the on!vitational took advantage of the venue’s technology, including its over four-story tall simulator screen and real-life putting and short-game areas, to deliver a golf experience unlike a traditional tournament.

The competition also featured unique in-match opportunities. Momentum Swing allowed the sweepstakes winners to chip into designated round spots on the green for significant bonus points while Celeb Shot allowed teams to choose any team member to take a shot, regardless of whose turn it was. All Axis offered a strategic element where teams could move the green 45 or 90 degrees in any direction after their opponent was on or close to the green to gain short game and putting advantages at key moments.

These elements ended up being major factors in the final. Grass League was down 6-0 on No. 6. They used their Celeb Shot to allow Kittleson to hit, and he delivered. He chipped it in from off the green to give Grass League their first points of the match. A 20-foot birdie putt on No. 7 by Hoselton pulled Team Grass League within two points, and the Momentum Swing was the deciding factor. Trailing 6-4 on No. 8, Team Grass League sweepstakes winner William K. chipped it into one of the designated spots, scoring six points, and clinching the comeback Championship victory.

"This was one of the best experiences of my life," said on!® sweepstakes and Team Grass League winner William K. in a post-match interview. "My team kept picking me up throughout the tournament, and I was able to deliver when it counted. Really thankful to on!® for putting on such a great event."

Beyond the competition, multi-platinum recording artist Flo Rida headlined Saturday's entertainment, bringing an energy-filled conclusion to two great days of golf. He performed some of his biggest hits and invited tournament winners and guests to join him onstage.

Honoring Veterans Through Golf

The on!vitational also featured a partnership with the Veteran Golfers Association (VGA), a nonprofit dedicated to enriching the lives of veterans and their family members through the camaraderie and sportsmanship of golf.

In addition to competing as one of the tournament's eight teams, the VGA participated in a special military salute recognizing U.S. Navy veteran and Medal of Honor recipient Edward C. Byers Jr., who attended the event. All proceeds from can sales at the on!vitational went towards supporting the VGA and its mission.

Relive the on!vitational

Fans 21 or older can relive the competition, winning moments, player highlights and entertainment through content available on the on! ® Instagram .

About on!® Nicotine Pouches

on!® and on! PLUS® nicotine pouches are designed for adult nicotine consumers 21+ looking for a satisfying, premium nicotine pouch experience. With six varieties and three nicotine strengths, on!® nicotine pouches deliver against a wide variety of adult consumer 21+ tastes and preferences. on! PLUS® nicotine pouches are designed with a proprietary NICOSILK™ mesh technology for a comfortable feel. on! PLUS**®** is available in Mint, Wintergreen & Tobacco flavors at 6, 9 and 12 mg strengths. on! PLUS® will also offer the same three strength options in exciting new flavors: Blueberry Mint, Mango Pineapple and Watermelon Mint (select stores only).

Helix Innovations LLC Profile

Helix Innovations LLC (Helix), an Altria company, offers a portfolio of oral nicotine pouch products for adult nicotine consumers 21+, including on!® and on! PLUS®. In December 2025, the U.S. Food and Drug Administration authorized the marketing of certain on! PLUS® variants.

Helix is committed to responsible marketing and preventing underage access to nicotine products. As an Altria operating company, Helix follows marketing practices designed to appeal to adult nicotine consumers 21+ while taking steps to limit reach to underage audiences.

No one under the age of 21 should use nicotine products. Nicotine is addictive, and nicotine products are not risk-free. on!® products are intended for adult nicotine consumers 21+.

Media Relations
Altria Client Services
https://www.altria.com/contact-us/media

Source: Altria Group, Inc.

10/15/2026

Download this Press Release PDF Format (opens in new window)

RICHMOND, Va.--(BUSINESS WIRE)-- Altria Group, Inc. (Altria) (NYSE: MO) will host a live audio webcast on Thursday, October 29, 2026, at 9:00 a.m. Eastern Time to discuss its 2026 third-quarter and nine-months business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com .

During the webcast, Sal Mancuso, Altria’s Chief Executive Officer, and Heather Newman, Altria’s Chief Financial Officer, will discuss the Company’s 2026 third-quarter and nine-months business results and answer questions from the investment community and news media.

The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.altria.com/webcasts . An archived copy of the webcast will be available on altria.com .

Investor Relations, Altria Client Services
(804) 484-8222

Media Relations, Altria Client Services
www.altria.com/contact-us/media

Source: Altria Group, Inc.

Prompts

Altria Group, Inc. (ticker MO), listed in United States.

Company History

Date Change Detail
Nov 3, 2008 Acquired Acquired Ust Inc (CIK 811669). Its filings from before the deal are on its own company page, not shown here.
Jan 29, 2003 Renamed PHILIP MORRIS COMPANIES INC → ALTRIA GROUP INC

ETFs Holding Altria Group, Inc.

ETF Weight in ETF Shares Market value As of
GQGU 6.20% 483,017 $ 34.753M Jun 30, 2026
SIXA 5.34% 389,257 $ 30.331M Nov 12, 2026
ROPE 5.12% 16,338 $ 1.27M Nov 18, 2026
VICE 4.70% 4,796 $ 345.072K Jun 30, 2026
LBAY 4.50% 9,940 $ 784.266K Nov 17, 2026
GEND 3.86% 2,746 $ 187.634K Jul 31, 2026
ZIG 3.66% 14,888 $ 1.153M Nov 18, 2026
NEWZ 3.29% 8,833 $ 680K Nov 18, 2026
AIVL 3.21% 185,709 $ 13.362M Jun 30, 2026
DDDD 3.16% 3,119 $ 246.089K Nov 17, 2026
DIVP 2.88% 21,756 $ 1.565M Jun 30, 2026
SEIQ 2.65% 244,506 $ 17.592M Jun 30, 2026
MBOX 2.55% 50,724 $ 3.93M Nov 18, 2026
SELV 2.43% 82,856 $ 5.961M Jun 30, 2026
DIVZ 2.35% 87,116 $ 6.268M Jun 30, 2026
DIVN 2.34% 105,013 $ 7.191M Aug 31, 2026
ABFL 2.31% 177,610 $ 12.136M Jul 31, 2026
ECML 2.23% 34,543 $ 2.68M Nov 18, 2026
QVAL 2.10% 197,279 $ 15.28M Nov 18, 2026
JHDV 2.00% 3,376 $ 242.903K Jun 30, 2026
NLSI short -1.96% -1,320 $ -88.889K Sep 30, 2026
MFUT 1.86% 17,596 $ 1.388M Nov 17, 2026
SAGP 1.84% 19,608 $ 1.411M Jun 30, 2026
PRMR 1.84% 24,560 $ 1.682M Aug 31, 2026
WBIG 1.78% 6,792 $ 488.684K Jun 30, 2026
QIDX 1.63% 9,271 $ 633.487K Jul 31, 2026
DSTL 1.59% 470,242 $ 33.834M Jun 30, 2026
QDVO 1.46% 150,029 $ 10.795M Jun 30, 2026
CGCV 1.46% 455,816 $ 35.964M Nov 16, 2026
TFPN 1.34% 26,143 $ 2.063M Nov 17, 2026
WTV 1.34% 548,219 $ 39.444M Jun 30, 2026
CAPE 1.22% 40,534 $ 2.916M Jun 30, 2026
RFDA 1.19% 14,370 $ 984.058K Aug 31, 2026
DIVD 1.19% 4,205 $ 330K Nov 18, 2026
PY 1.16% 35,522 $ 2.556M Jun 30, 2026
PAYR 1.14% 9,527 $ 650.98K Jul 31, 2026
UPSD 1.14% 19,474 $ 1.331M Jul 31, 2026
VUS 1.11% 2,899 $ 198.089K Jul 31, 2026
AFLG 1.06% 123,593 $ 9.751M Nov 16, 2026
HIDV 1.02% 30,473 $ 2.087M Aug 31, 2026
INFO 1.00% 115,219 $ 9.061M Nov 13, 2026
FDV 0.92% 118,547 $ 8.1M Jul 31, 2026
FTHI 0.91% 292,326 $ 23.065M Nov 16, 2026
AVIE 0.90% 1,894 $ 149.437K Nov 16, 2026
VFMF 0.87% 124,178 $ 8.504M Aug 31, 2026
CGDV 0.82% 3,973,088 $ 313.477M Nov 16, 2026
SFGV 0.81% 120,713 $ 9.35M Nov 18, 2026
VFMV 0.80% 53,223 $ 3.645M Aug 31, 2026
LSVD 0.79% 75,000 $ 5.125M Jul 31, 2026
ACIO 0.66% 225,703 $ 15.422M Jul 31, 2026
ADME 0.63% 27,226 $ 1.86M Jul 31, 2026
GQQQ 0.62% 13,239 $ 1.03M Nov 18, 2026
CLSE 0.61% 80,694 $ 5.526M Aug 31, 2026
FLSP 0.60% 78,508 $ 5.649M Jun 30, 2026
FLCV 0.56% 11,485 $ 786.493K Aug 31, 2026
PAPI 0.55% 30,576 $ 2.2M Jun 30, 2026
VFVA 0.52% 72,669 $ 4.976M Aug 31, 2026
GSPY 0.49% 42,685 $ 3.368M Nov 17, 2026
SIXL 0.46% 12,305 $ 958.806K Nov 12, 2026
FLDZ 0.44% 248 $ 17.844K Jun 30, 2026
ENHU 0.42% 501 $ 39.529K Nov 16, 2026
FTLS 0.42% 136,431 $ 0.00 Nov 16, 2026
BTAL 0.41% 16,192 $ 1.165M Jun 30, 2026
SCLZ 0.41% 1,111 $ 79.936K Jun 30, 2026
VSLU 0.36% 27,284 $ 1.963M Jun 30, 2026
FELV 0.33% 148,145 $ 10.659M Jun 30, 2026
FHEQ 0.31% 42,147 $ 2.88M Jul 31, 2026
XMAG 0.31% 8,494 $ 661.852K Nov 13, 2026
JEPI 0.29% 1,731,685 $ 134.136M Nov 17, 2026
SFTY 0.28% 32,193 $ 2.205M Aug 31, 2026
STOX 0.28% 9,091 $ 622.552K Aug 31, 2026
FELC 0.28% 301,409 $ 21.686M Jun 30, 2026
CDX 0.27% 8,641.5257 $ 669.373K Nov 17, 2026
AAUS 0.26% 17,112 $ 1.33M Nov 18, 2026
ACVF 0.24% 5,395 $ 368.64K Jul 31, 2026
LDRX 0.23% 8,595 $ 588.586K Aug 31, 2026
HBTA 0.22% 7,875 $ 539.28K Aug 31, 2026
IALT 0.21% 214,835 $ 16.95M Nov 16, 2026
JUSA 0.21% 24,066 $ 1.864M Nov 17, 2026
APUE 0.20% 74,308 $ 5.089M Aug 31, 2026
HELO 0.20% 120,612 $ 9.343M Nov 17, 2026
DFUS 0.19% 523,084 $ 40.759M Nov 12, 2026
TACU 0.19% 435 $ 34.322K Nov 17, 2026
NTSD 0.18% 909 $ 65.403K Jun 30, 2026
NTSX 0.18% 33,913 $ 2.44M Jun 30, 2026
VOXP 0.17% 141 $ 9,634.53 Jul 31, 2026
FYEE 0.16% 5,120 $ 349.85K Jul 31, 2026
GDE 0.16% 11,037 $ 755.814K Aug 31, 2026
DFAU 0.15% 249,132 $ 19.412M Nov 12, 2026
VFMO 0.14% 39,842 $ 2.728M Aug 31, 2026
DCOR 0.14% 821,057 $ 63.977M Nov 12, 2026
HCMT 0.14% 11,618 $ 793.858K Jul 31, 2026
JFLI 0.13% 797 $ 61.736K Nov 17, 2026
GVLU 0.12% 3,844 $ 303.292K Nov 17, 2026
LGDX 0.11% 1,946 $ 153.539K Nov 17, 2026
MSLC 0.11% 65,245 $ 4.468M Aug 31, 2026
FLCC 0.11% 2,100 $ 143.808K Aug 31, 2026
DUHP 0.10% 247,269 $ 19.267M Nov 12, 2026
AVLC 0.09% 18,470 $ 1.457M Nov 16, 2026
CSHP 0.07% 3,423 $ 270.075K Nov 16, 2026